Literature DB >> 8600219

Patients' strategies for coping with auditory hallucinations.

D M Carter1, A Mackinnon, D L Copolov.   

Abstract

Many patients with psychotic disorders experience persistent auditory hallucinations despite rigorous pharmacological treatment. The experience of auditory hallucinations can heighten anxiety and depression. The high risk of suicide among patients experiencing auditory hallucinations is well recognized. Research in this area has been restricted to small samples or has collected information only on the use of such strategies without investigating their efficacy. The Mental Health Research Institute Unusual Perceptions Schedule incorporates a module focusing on coping strategies. This schedule was administered to 100 subjects, with the aim of investigating the relationship between strategy use and effectiveness, as well as the characteristics of subjects and their disorders. Eighty-one percent of the subjects were worried or upset by their hallucinations. The majority (66%) of the subjects reported they had ways of managing the voices, and 69% of them described at least some success using one or more strategies. There was a striking lack of correspondence between the number of subjects using a method and its related efficacy. No relationship was found between length of illness and number of strategies used. Multidimensional scaling of use and efficacy data revealed three groups of strategies. These groups do not correspond to previous classifications made on the basis of features of the strategies themselves. The pattern of results also suggests that training methods might be used to increase the options for patients troubled by auditory hallucinations.

Entities:  

Mesh:

Year:  1996        PMID: 8600219     DOI: 10.1097/00005053-199603000-00004

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  8 in total

1.  Capturing coping with symptoms in people with a diagnosis of schizophrenia: introducing the MACS-24.

Authors:  Maarten Bak; Philippe Delespaul; Lydia Krabbendam; Karola Huistra; Wil Walraven; Jim van Os
Journal:  Int J Methods Psychiatr Res       Date:  2009       Impact factor: 4.035

2.  Fostering Recovery from Life-Transforming Mental Health Disorders: A Synthesis and Model.

Authors:  Carla A Green
Journal:  Soc Theory Health       Date:  2004-11-01

3.  Knowledge and insight in relation to functional remission in patients with long-term psychotic disorders.

Authors:  Malin Alenius; Margareta Hammarlund-Udenaes; Per Hartvig; Leif Lindström
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-07-21       Impact factor: 4.328

4.  Targeted neural network interventions for auditory hallucinations: Can TMS inform DBS?

Authors:  Joseph J Taylor; John H Krystal; Deepak C D'Souza; Jason Lee Gerrard; Philip R Corlett
Journal:  Schizophr Res       Date:  2017-09-29       Impact factor: 4.939

5.  Effects of Aripiprazole and Haloperidol on Fos-like Immunoreactivity in the Prefrontal Cortex and Amygdala.

Authors:  Jong-Il Park; Tong Zhao; Guang-Biao Huang; Zhi-Yan Sui; Chun-Rong Li; Eui-Hyeog Han; Young-Chul Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

6.  Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations in Patients with Schizophrenia: A Randomized Controlled, Cross-over Study.

Authors:  Eun-Ji Kim; Seonguk Yeo; Inho Hwang; Jong-Il Park; Yin Cui; Hong-Mei Jin; Hyung Tae Kim; Tae-Young Hwang; Young-Chul Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

7.  Online Methods of Managing Auditory Hallucinations: A New Trend to Understand Psychopathology.

Authors:  Manoj Kumar Sharma; Poornima Mahindru
Journal:  Indian J Psychol Med       Date:  2017 May-Jun

8.  Neural Signature for Auditory Hallucinations in Schizophrenia: A High-Resolution Positron Emission Tomography Study with Fludeoxyglucose (18F).

Authors:  Jong-Hoon Kim; Young Don Son; Jeong-Hee Kim; Hyo-Jong Lee; Nam-In Kang; Gyung Ho Chung; Jong-Il Park; Yin Cui; Woo-Sung Kim; Young-Chul Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.